DEF: Envoy Medical Seeks Shareholder Approval for Warrant Issuance

Envoy Medical, Inc. calls a Special Meeting to approve the issuance of warrants and underlying Class A Common Stock to comply with Nasdaq listing rules following a recent securities offering.

Summary

• A Special Meeting of Stockholders will be held on November 26, 2025, at 9:00 a.m. local time.
• The primary purpose is to approve the issuance of warrants to purchase shares of Class A Common Stock, and the issuance of Class A Common Stock underlying such warrants, to comply with Nasdaq Listing Rule 5635(d).
• This approval relates to Private Warrants to purchase up to 5,725,206 shares and Placement Agent Warrants to purchase up to 143,130 shares, plus an additional 7.5% of exercised Private Warrants.
• The Private Placement, which included the issuance of these warrants, closed on September 23, 2025.
• Private Warrants have an exercise price of $1.31 per share, and Placement Agent Warrants have an exercise price of $1.6375 per share.
• The Board of Directors unanimously recommends a vote FOR both the Issuance Proposal and the Adjournment Proposal.
• Glen A. Taylor and affiliated entities, collectively owning approximately 43.2% of the Company's Class A Common Stock, have agreed to vote in favor of proposals unanimously approved by the Board for Nasdaq compliance purposes.

Sentiment

Score: 6

Explanation: The filing outlines a necessary procedural step for a capital raise that has already occurred. While it introduces future dilution, it secures potential funding and ensures Nasdaq compliance. The unanimous board recommendation and major shareholder commitment reduce uncertainty, leading to a neutral to slightly positive outlook on the company's ability to manage its capital structure and regulatory obligations.

Positives

• Secured potential future funding of approximately $8.4 million in gross proceeds if all Private Placement Warrants are exercised.
• The approval ensures compliance with Nasdaq Listing Rule 5635(d), which is critical for maintaining the company's listing.
• A major shareholder, Glen A. Taylor, owning approximately 43.2% of Class A Common Stock, has committed to vote in favor of the proposal, increasing the likelihood of approval.

Negatives

• Existing stockholders will experience dilution of their percentage ownership upon the future exercise of the Private Placement Warrants, which could result in an aggregate of 6,297,726 additional shares of Class A Common Stock outstanding.
• The potential sale of these additional shares into the public market could materially and adversely affect the market price of Class A Common Stock.
• Failure to approve the Issuance Proposal would prevent the company from receiving the approximately $8.4 million in potential proceeds from warrant exercises.
• Non-approval would lead to substantial additional costs and expenses, as the company would be required to seek stockholder approval every 90 days for up to five years until the warrants are no longer outstanding.

Risks

• Failure to obtain stockholder approval for the Issuance Proposal would prevent the exercise of Private Placement Warrants, leading to a loss of up to approximately $8.4 million in potential gross proceeds.
• Incurrence of substantial additional costs and expenses from repeated proxy solicitations every 90 days for up to five years if approval is not obtained.
• Dilution of existing stockholders' percentage ownership upon the future exercise of Private Placement Warrants.
• Potential adverse impact on the market price of Class A Common Stock due to the sale of additional shares into the public market.

Future Outlook

The company anticipates receiving up to approximately $8.4 million in gross proceeds if all Private Placement Warrants are exercised, which would support funding operations. Failure to approve the Issuance Proposal would prevent these proceeds and incur significant ongoing costs for repeated proxy solicitations every 90 days for up to five years, potentially impacting the company's ability to fund operations, long-term performance, and strategic goals.

Management Comments

• The Board of Directors unanimously recommends that the stockholders vote FOR the Issuance Proposal.
• The Board of Directors unanimously recommends that the stockholders vote FOR the approval of the Adjournment of the Special Meeting, if necessary.

Industry Context

This filing reflects a standard corporate governance procedure for publicly traded companies to seek shareholder approval for significant equity issuances, particularly when they exceed certain thresholds (such as Nasdaq's 20% rule) or involve warrants. This is a common step in capital raising activities to ensure compliance with listing requirements and maintain market access, which is vital for growth and operational stability in the industry.

Comparison to Industry Standards

• The requirement for shareholder approval under Nasdaq Listing Rule 5635(d) is a standard corporate governance benchmark for companies listed on Nasdaq, ensuring transparency and shareholder oversight for large equity issuances outside of public offerings.
• The company's strategy to secure a voting agreement with a major shareholder (Glen A. Taylor, 43.2% ownership) to ensure the passage of the proposal is a common practice to de-risk critical shareholder votes, similar to how other companies might engage institutional investors or proxy advisory firms.

Corporate Governance

Related Party Transactions

• Glen A. Taylor (a former director and significant shareholder) and his affiliated entities (GAT Funding, LLC and Taylor Sports Group, Inc.) are parties to a Voting and Warrant Extension Agreement dated September 4, 2025, committing their votes for Nasdaq compliance proposals.
• GAT Funding, LLC, controlled by Mr. Taylor, holds 4,810,384 shares of Class A Common Stock, 869,565 shares issuable upon conversion of Series A Preferred Stock, and 2,750,000 shares issuable upon exercise of stock purchase warrants, all issued in connection with debt financing provided by GAT to the Company.

Stakeholder Impact

• Shareholders: Will face dilution of their ownership interests upon the exercise of the Private Placement Warrants (up to 6,297,726 additional shares). However, approval ensures Nasdaq compliance and potential capital inflow, which could support long-term company stability.
• Company (Management/Operations): Approval of the Issuance Proposal is crucial for compliance with Nasdaq listing rules and enables the company to realize up to approximately $8.4 million in gross proceeds from warrant exercises, which can be used to fund operations. Non-approval would lead to significant recurring costs and hinder funding.
• Warrant Holders (Purchasers & Placement Agent): Their warrants will become exercisable upon shareholder approval, allowing them to acquire Class A Common Stock at specified exercise prices.

Next Steps

• Hold the Special Meeting of Stockholders on November 26, 2025, to vote on the Issuance Proposal and the Adjournment Proposal.
• If the Issuance Proposal is approved, the Private Placement Warrants will become exercisable.
• If the Issuance Proposal is not approved, the company will be required to seek stockholder approval every 90 days until the Private Placement Warrants are no longer outstanding, incurring substantial additional costs.

Key Dates

Recommendation

The filing primarily addresses a procedural vote for a capital raise that has already occurred in part. While the potential dilution from warrant exercise is a negative, the capital infusion (up to $8.4 million) and ensuring Nasdaq compliance are crucial for the company's stability and future operations. The commitment from a major shareholder to vote in favor reduces uncertainty regarding the approval. Given these factors, a 'hold' recommendation is appropriate as the immediate impact is largely procedural, with long-term implications dependent on the company's use of the capital and future performance.

Keywords

Envoy Medical, SEC filing, DEF 14A, proxy statement, Nasdaq, stock warrants, capital raise, shareholder vote, dilution, corporate governance, COCH, private placement, registered offering